All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

October 16th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Two FCS Manuscripts Published in NEJM Within Two Months Co-Authored by Manish R. Patel, MD

October 16th 2023

Florida Cancer Specialists & Research Institute, LLC Director of Drug Development Manish Patel, MD is the co-author for two manuscripts published in the New England Journal of Medicine within two months.

FDA Grants Priority Review to Osimertinib Plus Chemotherapy for EGFR+ Locally Advanced or Metastatic NSCLC

October 16th 2023

The FDA has granted priority review to the supplemental new drug application seeking the approval of osimertinib in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

European Commission Approves Adjuvant Pembrolizumab for High-Risk NSCLC

October 16th 2023

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

New Data Bring Excitement, Raise Questions in Advanced RCC

October 16th 2023

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer

October 16th 2023

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Montefiore Einstein Comprehensive Cancer Center Unveils New Destination for Breast Care

October 15th 2023

Montefiore Einstein Comprehensive Cancer Center opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.

Infection Risk Increases With Longer Surgical Duration in Lower Extremity Bone Tumors

October 15th 2023

R. Lor Randall, MD discusses the primary results of the PARITY study and their implications for the use of antibiotics for patients with lower extremity bone tumors undergoing surgery and highlighted the findings from the secondary analysis of the study on the effect of surgical duration on risk of infection

Tarek Eldawy, MD joins Florida Cancer Specialists & Research Institute

October 14th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome Board-certified hematologist and medical oncologist Tarek Eldawy, MD to the statewide practice.

Ceralasertib/Durvalumab Demonstrates Efficacy in RAS-Mutant Advanced NSCLC Post Immune Checkpoint Blockade

October 14th 2023

Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.

FDA Approves Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

October 14th 2023

The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of adult and pediatric patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors

October 13th 2023

Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.

CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma

October 13th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Raphael Bosse, MD, PhD Joins Naples-Goodlette

October 13th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist Raphael Bosse, MD, PhD, has joined the statewide practice.

NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

October 13th 2023

Treatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung cancer.

RWJBarnabas Health Recognized Among 2023’s “100 Hospitals and Health Systems with Great Oncology Programs" by Becker’s Hospital Review

October 13th 2023

RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, has been named among Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs for 2023.

Zanubrutinib Plus Obinutuzumab Approaches EU Approval in R/R Follicular Lymphoma

October 13th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib in combination with obinutuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.

FDA Approves Companion Diagnostics for Encorafenib/Binimetinib in BRAF V600E+ Metastatic NSCLC

October 13th 2023

The FDA has approved FoundationOne® CDx and FoundationOne Liquid CDx for use as companion diagnostics to identify patients with metastatic non–small cell lung cancer harboring BRAF V600E mutations who may benefit from treatment with the combination of encorafenib plus binimetinib.

The Bleak Fiscal Implications of Advanced Cancer as a Chronic Illness

October 13th 2023

Maurie Markman, MD, highlights the rather profound fiscal implications of the combined effect of 2 quite different but closely related components of the rapidly evolving cancer treatment paradigm.

Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial

October 13th 2023

The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.